Whole genome sequencing of *Mycobacterium tuberculosis* isolates and clinical outcomes of patients treated for multidrug-resistant tuberculosis in Tanzania

Bugwesa Z. Katale1,2†, Peter M. Mbelele3,4†, Nsiande A. Lema5, Susana Campino6, Stephen E. Mshana7, Mark M. Rweyemamu8, Jody E. Phelan9, Julius D. Keyyu2, Mtebe Majigo1, Erasto V. Mbugi9, Hazel M. Dockrell6, Taane G. Clark6,10, Mecky I. Matee1* and Stellah Mpagama3

**Abstract**

**Background:** Tuberculosis (TB), particularly multi- and or extensive drug resistant TB, is still a global medical emergency. Whole genome sequencing (WGS) is a current alternative to the WHO-approved probe-based methods for TB diagnosis and detection of drug resistance, genetic diversity and transmission dynamics of *Mycobacterium tuberculosis* complex (MTBC). This study compared WGS and clinical data in participants with TB.

**Results:** This cohort study performed WGS on 87 from MTBC DNA isolates, 57 (66%) and 30 (34%) patients with drug resistant and susceptible TB, respectively. Drug resistance was determined by Xpert® MTB/RIF assay and phenotypic culture-based drug-susceptibility-testing (DST). WGS and bioinformatics data that predict phenotypic resistance to anti-TB drugs were compared with participant’s clinical outcomes. They were 47 female participants (54%) and the median age was 35 years (IQR: 29–44). Twenty (23%) and 26 (30%) of participants had TB/HIV co-infection BMI < 18 kg/m2 respectively. MDR-TB participants had MTBC with multiple mutant genes, compared to those with mono or polyresistant TB, and the majority belonged to lineage 3 Central Asian Strain (CAS). Also, MDR-TB was associated with delayed culture-conversion (median: IQR (83: 60–180 vs. 51:30–66) days). WGS had high concordance with both culture-based DST and Xpert® MTB/RIF assay in detecting drug resistance (kappa = 1.00).

**Conclusion:** This study offers comparison of mutations detected by Xpert and WGS with phenotypic DST of *M. tuberculosis* isolates in Tanzania. The high concordance between the different methods and further insights provided by WGS such as PZA-DST, which is not routinely performed in most resource-limited-settings, provides an avenue for inclusion of WGS into diagnostic matrix of TB including drug-resistant TB.

**Keywords:** Whole genome sequence, *Mycobacterium tuberculosis*, Multidrug-resistant tuberculosis, Time-to-culture-conversion, Treatment-outcomes
Background

Tuberculosis (TB), caused by the Mycobacterium tuberculosis complex (MTBC), is the leading cause of mortality, killing about 2 million people each year globally [1]. The highest TB mortality and morbidity occurs in low and middle income countries like Tanzania [1, 2]. HIV infection is the most important single predictor of TB incidence across the African continent [3]. This is critical because HIV/AIDS is likely to increase in the risk of progression TB infection by 30 times, due to impairment on the immune system [3]. Sub-Saharan Africa carries a disproportionate burden of HIV, accounting for more than 70% of the global burden of infection [4]. For instance, in 2017, nearly 2.5 million people who contracted TB lived in sub-Saharan Africa, and 665,000 of them died from the disease [5]. The recent introduction of the XpertMTB/Rif assay (Cepheid, USA) has shown an increase in detection of drug resistance TB patients and the detection of multidrug-resistant TB (MDRTB) has increased three- to eight-fold compared to conventional testing [6]. Despite the gaps in documentation of MDRTB cases in several Sub-Saharan African countries (SSA), pooled analysis that involved several studies reported a prevalence of 2.1% of MDRTB in new cases, signifying a low prevalence of MDRTB cases in SSA [7]. The relatively low prevalence of MDRTB in SSA might be attributed by the recent introduction of rifampicin in Africa, by the use of rifampicin-free treatment regimens in the continuation phase (during months three to eight), by the growing use of directly observed treatment as recommended under the directly observed treatment, short course (DOTS) strategy, and by the use of fixed-dose combination tablets in a few countries [8, 9].

Tanzania is among African countries south of Sahara with the highest burdens of TB, with an estimated 295 TB cases per 100,000 adults. The National anti-tuberculosis drug resistance survey conducted in 2010 in Tanzania found the resistance to any of the four first-line drugs in new patients to be 8.3%, while the prevalence of MDR-TB was 1.1%. However, the crude prevalence for any resistance and for MDR-TB in retreated cases increased to 20.6 and 3.9% respectively [10].

The emergence of resistant strains of MTBC to antibacterial drugs like rifampicin (RIF), isoniazid (INH), pyrazinamide (PZA), ethambutol (EMB), streptomycin (SM) among others; and the emergence of HIV in the 1980s led to resurgence of TB [11]. Multidrug resistant TB (MDR-TB), defined as resistance to at least RIF and INH, is usually caused by MTBC strains that harbour mutations in rpoB, katG and inhA genes associated with RIF and INH resistance. Globally, MDR-TB claims over 580,000 people’s lives annually [12]. About 10% of MDR-TB isolates exhibit resistance to fluoroquinolones (FQs) and second-line-injectable drugs (SLIDs) (aminoglycosides/cyclic-polypeptides), referred to as extensive drug resistant TB (XDR-TB), which challenges clinical management [2, 13, 14]. Patients with XDR-TB are infected with MTBC that have mutations in rrs, tlyA or eis promoter region (SLI related) and gyrA or gyrB genes (FQ related). Clinical management of both MDR-TB and XDR-TB is very complex and there are different treatment regimens [15]. About 50 and 70% of patients treated for MDR-TB and XDR-TB have unfavourable treatment outcomes, respectively. Although XDR-TB is rare in Tanzania, cohort review reports of patients treated for MDR-TB show that treatment success is only 75%. However, control and prevention measures should be strengthened in the country to reduce MDRTB related morbidity and mortality. To improve treatment outcomes and control escalation of MDR/XDR-TB; early, rapid and accurate diagnostic methods are required to detect and decipher susceptibility profile of the MTBC to anti-TB drugs in TB endemic settings such as Tanzania.

As in other TB endemic settings, Tanzania has deployed rapid molecular methods for dual detection of MTBC and susceptibility to either RIF alone or along with INH and second-line injectable and fluoroquinolones. For example, while the XpertMTB/Rif assay (Cepheid, USA) detects MTBC and provides information about susceptibility to RIF only [16], the genotype MTBDRplus and MTBDRsl assays (Hain Life sciences, Germany) detect mutations that are strongly associated with multiple types of MDR-TB and also XDR-TB respectively [17, 18]. These assays have potential to guide implementation of the new WHO shorter regimen for treating MDR-TB [15, 19]. Unlike Whole genome sequencing (WGS), these PCR-probe based assays have limited anti-TB drug-susceptibility value especially if mutations occur outside the target region [20]. In recent years, WGS platforms have become an alternative diagnostic in addressing probe-based assay limitations. WGS can identify genotypes predictive of drug-resistance phenotype within the entire region of microbial genome and has potential to determine genetic relatedness and identify transmission dynamics necessary in guiding clinical decisions. There is a need to sequence as many MTBC strains as possible, build libraries of single nucleotide polymorphisms (SNPs) and other variants, compare the relatedness of MTBC strains, and correlate variation with clinical progress or outcomes as a whole. Based on this, we performed WGS for the first time on isolates sourced from patients treated for MDR-TB at Kibong’oto Infectious Diseases Hospital (KIDH) in Tanzania. These data will provide a baseline set of the types and variations in TB in Tanzania. Clinical and laboratory information such as treatment regimen, phenotypic susceptibility profile, prior history of treatment with first line anti-TB drugs, HIV status,
culture conversion rate and treatment outcomes were available for analysis.

Results
Baseline demographic and clinical characteristics of study participants
A total of 87 study participants with positive MTBC culture results were included in the genetic study of whom, 47 (54%) were females. The median age was 35 (Interquartile range = 29–44) years (Table 1). Twenty (23%) were co-infected with HIV and had a median CD4 counts of 246 (IQR =119–388) cells/mm³.

Association of clinical information with genetic drug resistance
Table 2 summarizes demographic and clinical characteristics of TB patients. We found association between previous history of TB treatment and phenotypic drug resistance (OR, 0.01 95% CI: 0.0003–0.0995, p = < 0.001) (Table 2).

Analysis of mutations associated with phenotypic drug resistance to anti-TB drugs
Of the 87 MTBC isolates sequenced, 57 (65.5%) had at least one mutation in a gene that was predictive for 7 anti-drugs (Table 3). The concordance between phenotypic DST and WGS was 97% for RIF (DST: WGS; 26:28 isolates), 81% INH (DST: WGS; 40:51 isolates) and 95% for SM (DST: WGS; 8:11 isolates) (kappa = 1.00). Moreover, the concordance between Xpert® MTB/RIF (Cepheid, USA) and WGS for detection of RIF resistance was 95% (8:11 isolates) (kappa = 1.00). Substitution of serine to threonine at codon 315 (S315T) of the katG gene accounted for 50 (94.3%) of mutations (Table 3). The common mutation associated with phenotypic resistant to RIF was S450L (substitution of serine to leucine) accounted for 96% (26/27) of the detected RIF resistance. Of the 57 isolates, 29 (33%) had mutations in the embB gene and Q497R was the common accounting for 7 (36.8%) (Table 3). In addition, our analysis revealed pncA deletion involving Rv2044c in two drug resistance isolates (MDRTB & polyresistance isolates) that contributed 5.3% (1 isolates) of MDRTB and other resistance pattern (Table 3). Patients with MDR-TB had highly diverse mutations as compared to monoresistance (Table 3). We found 2 pre patients harbouring XDRTB isolates. The drug resistance mutations involving either rrs or gyrB genes against AMK and FQs respectively were detected in low proportions among DR resistance isolates (Table 3). These isolates had mutation either at the rrs gene involving substitution of C to T at codon 51 (C517T) or gyrB gene which involved replacement of R by C at codon 446 (R446C). MTBC isolates from drug susceptible patients had no mutations in genes encoding for INH, RFP, PZE, STM and EMB.

Treatment outcome and culture conversion rates among the drug resistance TB isolates
Of the 57 study participants with mutation(s) to at least one of the anti-TB drugs, 47 (82.5%) had successful treatment, 3 (5.3%) died, and 7 (12.3%) defaulted (Table 4). Three patients (2MDR-TB and 1 with polyresistant) died 9 months after enrolment, during which they were in a continuous phase of anti-mycobacterial medications. The median (IQR) culture conversion rates were 51 (30–66) days and 83 (60–180) days for participants with mono/polyresistant and MDR/XDR-TB, respectively (Table 4).

Phylogenetic analysis of the drug resistance TB isolates
Phylogenetic analysis revealed that the DR-TB strains were heterogeneously distributed in lineages 1 to 7 (Fig. 1). The Central Asian Strains (CAS) (lineage 3) predominated in the MTBC strains and accounted for 48.3% (42/87) of the isolates, followed by lineage 4 (32/87; 36.8%), lineage 1 (10/87; 11.5%), lineage 2 (3/87; 3.4%) and 1 (1.1%). Of the 24 MDR isolates, 15 (62.5%)
isolates belonged to lineage 3 (CAS), 5 (20.8%) isolates were lineage 4 (Latin American Mediterranean, LAM), 2 (8.3%) isolates were lineage 2 and 2 (8.3%) isolates originated from lineage 1 (East African Indian, EAI) (Table 5).

Discussion
In this study, we found high concordance between WGS and conventional culture-based DST in predicting phenotypic drug resistance to anti-TB drugs, ranging from 81% for INH to 97% for RIF, and 95% concordance with Xpert® MTB/RIF (Cepheid, USA) for RIF. These findings are in agreements with those previously reported in different TB endemic settings [21–24]. The ability of Xpert® MTB/RIF and phenotypic detection of TB drug resistance cannot be underscored as it can pave a way to complementary and confirmatory WGS in early detection of resistance. Studies have shown phenotypic susceptibility tests to serve as reference standards [25], and that both Xpert assay and DST can provide information on polyresistance in pre-XDR-TB [26] despite varying sensitivities [27, 28].

The current practice in diagnosing drug resistant tuberculosis is through the WHO-approved probe-based assays like Xpert® MTB/RIF (Cepheid, USA) for RIF [16] and either genotype MTBDRplus for RIF and INH or genotype MTBDRsl (Hain Lifesciences, Germany) for aminoglycosides/capreomycin and fluoroquinolones that must be confirmed with culture-based DST [29]. Unlike WGS, these assays not only have limited DST range to identify hot-spot resistant determining regions but they also cannot inform transmission dynamics [30, 31]. The high concordance supports adoption of WGS as an alternative diagnostic tool to complement results from DST of all previously treated presumptive or confirmed rifampicin resistance cases in clinical settings. Although the facilities are not yet available the approach can be advocated in future clinical settings to enable reduction in unnecessary laboratory diagnostic time delays between identification of patients suspected of MDR-TB and initiation of treatment [29]. The potential for WGS to provide a rapid and comprehensive view of the genotype and reliable prediction of the drug susceptibility phenotype has been reported elsewhere [23, 32, 33]. This is an important platform to inform about susceptibility profile drugs like pyrazinamide (PZA), which is prescribed empirically in Tanzania and other resource limited countries. PZA kills semi-dormant bacilli and has synergistic activity with bedaquiline (BDQ), a key core drug in the currently recommended all-oral injectable free MDR-TB regimen(s). This synergism supports design of a shortened treatment regimens, which favours healthy patient outcomes [34].

In our study, the WGS uncovered 2 pre patient harbouring XDR-TB isolates, which were also detected by phenotypic DST at our hospital and later cured after MDR-TB treatment. This finding adds value to WGS as a potential molecular tool to complement phenotypic-DST and other molecular assay such Gene Xpert® MTB/RIF (Cepheid, USA) MDR-TB results for informed

Table 2 Demographic and clinical characteristics of drug resistance TB patients

| Variables, n (%) | DR-TB (n = 57) | DS-TB (n = 30) | OR (95% C.I) for DR-TB | p values |
|------------------|----------------|---------------|------------------------|----------|
| Gender           |                |               |                        |          |
| Male             | 26             | 14            | 0.96 (0.36–2.56)       | 0.93     |
| Female           | 31             | 16            |                        |          |
| Age (years)      |                |               |                        |          |
| < 33             | 21             | 10            |                        |          |
| ≥ 33             | 36             | 20            | 1.17 (0.42–3.34)       | 0.55     |
| HIV status       |                |               |                        |          |
| Negative         | 41             | 26            | 2.5 (0.70–11.47)       | 0.12     |
| Positive         | 16             | 4             |                        |          |
| CD4 count (n = 20) |                |               |                        |          |
| < 200            | 6              | 2             |                        |          |
| ≥ 200            | 10             | 2             | 0.6 (0.04–10.62)       | 0.65     |
| Previous history of TB treatment | | | | |
| New              | 16             | 29            | 0.01 (0.0003–0.0995)   | <0.001   |
| Retreatment      | 41             | 1             |                        |          |
| Body mass index  |                |               |                        |          |
| < 16–18.5        | 19             | 7             |                        |          |
| ≥ 18.5           | 38             | 23            | 1.6 (0.55–5.34)        | 0.33     |
Table 3  Frequency and distribution of mutations associated with drug resistance M. tuberculosis

| Drug  | Target gene | mutation   | n (%) in monoresistance | n (%) in MDR-TB strains | n (%) in other resistance pattern | Total (N) |
|-------|-------------|------------|--------------------------|-------------------------|----------------------------------|-----------|
| RIF (n = 27) | rpoB | S450L   | 4 (14.8) | 16 (59.3) | 6 (22.2) | 26 |
|       |           | D435Y   | 1 (3.7)  | 1 (3.7)  | –        | 1 |
| INH (n = 55) | katG | S315T   | 10 (18.2) | 24 (43.6) | 16 (29.1) | 50 |
|       |           | S302R   | –         | 1 (1.8)  | 1 (1.8)  | 2 |
|       |           | N138S   | –         | 1 (1.8)  | –        | 1 |
|       |           | anyR′-ahpC | CS2T | –         | 1 (1.8)  | 1 |
|       |           | CS4T    | –         | 1 (1.8)  | –        | 1 |
| EMB (n = 29) | embB | Y319C   | –         | –        | 1 (3.4)  | 1 |
|       |           | Q497R   | –         | 6 (20.9) | 2 (6.9)  | 8 |
|       |           | G406D   | –         | –        | 1 (3.4)  | 1 |
|       |           | G406S   | –         | 2 (6.9)  | 3 (10.3) | 5 |
|       |           | M306L   | –         | 1 (3.4)  | –        | 1 |
|       |           | M306I   | –         | 1 (3.4)  | –        | 1 |
|       |           | G406A   | –         | 3 (10.3) | –        | 3 |
|       |           | M306V   | –         | 2 (6.9)  | –        | 2 |
|       |           | Y334H   | –         | 1 (3.4)  | –        | 1 |
|       |           | M306T   | –         | 1 (3.4)  | –        | 1 |
|       |           | EmbC-embA | C16T | 1 (3.4)  | 3 (10.3) | 5 |
| PZA (n = 19) | pncA | V128G   | –         | 8 (42.1) | –        | 8 |
|       |           | A193AT  | –         | –        | 1 (5.3)  | 1 |
|       |           | G17D    | –         | –        | 1 (5.3)  | 1 |
|       |           | D8N     | 1         | –        | –        | 1 |
|       |           | L85P    | –         | –        | 1 (5.3)  | 1 |
|       |           | A46V    | –         | 1 (5.3)  | –        | 1 |
|       |           | P69L    | –         | 1 (5.3)  | –        | 1 |
|       |           | Q10R    | –         | 1 (5.3)  | –        | 1 |
|       |           | D49G    | –         | 1 (5.3)  | –        | 1 |
|       |           | D63A    | –         | 1 (5.3)  | –        | 1 |
|       |           | Rv2044c | –         | 1 (5.3)  | 1 (5.3)  | 2 |
| STR (n = 3) | rpsL | K43R    | –         | 2 (100)  | –        | 2 |
|       |           | rs      | CS17T    | 1 (100)  | –        | 1 |
| FLO (n = 1) | gyrB | R446C   | –         | 1 (100)  | –        | 1 |
| AMK (n = 2) | rs    | CS17T   | –         | 2 (100)  | –        | 2 |

decision-making prior to anti-tuberculosis therapy. For effective use particularly in low- and middle-income countries, WGS must be robust, easy to use, and affordable.

We also found that the majority of the MTBC isolates from DR-TB participants had mutations in genes predictive of phenotypic resistance to all 7 anti-TB drugs tested including INH (katG), RIF (rpoB), EMB (embB, embC-embA), FQs (gyrB) and second line injectable drugs (rrs) (Table 3). The commonest mutations found in this study was S450L for rpoB (26/27), S315T on katG (51/56), Q497R (8/29) and G406S (5/29) on embB, C16T (5/29) on embC-embA, V128G (7/19) on pncA and K43R on rpsL genes are in keeping with findings reported elsewhere [35, 36]. As expected, patients with MDR-TB had multiple mutations in these genes, confirming the previous concept that drug resistance in mycobacteria spp., and other bacteria evolves as they accumulate mutations either de novo or after multiple and longer exposure to antibiotics [37, 38]. This high diversity of mutations among DR-TB patients suggests on-going transmission of MDR-TB strains rather than acquisition through random mutation and selection of drug resistance strains [37, 39]. In addition, our analysis revealed a large deletion that involved Rv2044c in
### Table 4 Drug resistance TB patients' susceptibility testing, genotypic resistance, culture conversion rate and treatment outcome (n = 57)

| Drug pattern resistance (N = 57) | Type of mutation in drug target genes | Phenotypic DST | Mean culture conversion in days | Treatment outcome |
|----------------------------------|---------------------------------------|----------------|-------------------------------|------------------|
|                                  | INH katG oxyR'-ahpC RIF rpoB EMB embB embC-embA | PZA pncA SM rpsL rrs FQ gyrB AMK | resistance | Success | Defaulted | Died |
| Monoresistance (n = 17)          | S315T S450L M306I C16T D8N K43R C517T | 51             | 16 1 0                        |
| MDR-TB (n = 24)                  | S315T S450L M306I C16T D8N K43R C517T | 83             | 17 5 2                        |
| Others e.g. polyresistance (n = 16) | S315T S450L M306I C16T D8N K43R C517T | 66             | 14 1 1                        |

Katale et al. BMC Genomics (2020) 21:174
the PZA resistance isolates. Such isolates also possessed mutations either in drug resistance genes for RIF or INH. INH, FQs and SLIDs are used for shorter MDR-TB treatment regimes. However, mutations involving genes associated with INH, EMB, FQs and SLIDs resistance affect the selection of appropriate treatment regimens [15, 19]. INH and EMB have been in use for several decades either as part of the standard treatment regimen for drug susceptible TB and INH monotherapy as infection preventive therapy for HIV infected individuals [40]. On the other hand, MTBC isolates from DS-TB participants had no mutations in genes encoding for INH, RIF, PZA, SM and EMB, which is in keeping with Cryptic consortium findings that reported susceptibility profiles for all isolates unless uncharacterized mutations or missing key nucleotide calls were present [41]. We found 2 pre-XDR-TB patients possessing R446C and C517T mutations in the gyrB and rrs genes, in addition S315T, S450L, G406A and C517T mutations in the katG, rpoB, embB and rrs genes respectively. At this juncture, it is worthwhile to translate these

---

Fig. 1: Phylogenetic tree showing relationship of *M. tuberculosis* drug resistance strains, and pattern of drug resistance.
| Isolate ID | Lineages | Spoligotype | WGS cluster | Genotype at drug loci |
|-----------|----------|-------------|--------------|----------------------|
|           |          |             |              | rpoB  katG  rrs pncA  gyrB  rs  embB  embC  embA  ST  rpsL  rrs |
| 1         | lineage3 | CAS         | MDR          | S450L  S31ST | Large deletion pncA Rv2044c |
| 7         | lineage3 | CAS         | MDR          | S450L  S31ST |
| 11        | lineage4 | LAM         | DR           | D8N     |
| 20        | lineage4 | LAM         | DR           | D435Y   |
| 38        | lineage3 | CAS         | MDR          | S450L  N138S | M306V, Q497R, G406A |
| 42        | lineage3 | CAS         | DR           | S31ST   |
| 51        | lineage4 | LAM         | DR           | S31ST   |
| 52        | lineage1 | EAI         | DR           | S31ST   | Y319C |
| 63        | lineage3 | CAS         | MDR          | S450L  S31ST | M306I |
| 71        | lineage3 | CAS         | DR           | S31ST   | G17D  Q497R |
| 75        | lineage3 | CAS         | DR           | S31ST   | G406D |
| 81        | lineage4 | LAM         | DR           | S31ST   | L85P  G406S, M306L |
| 82        | lineage3 | CAS         | MDR          | S450L  S31ST | V128G |
| 85        | lineage3 | CAS         | MDR          | S450L  S31ST | CS17T |
| 92        | lineage4 | LAM         | DR           | S31ST   | CS17T |
| 98        | lineage4 | LAM         | DR           | S31ST   |
| 104       | lineage4 | LAM         | DR           | S31ST   |
| 106       | lineage4 | LAM         | MDR          | S450L  S31ST | Q10R |
| 110       | lineage4 | LAM         | DR           | S31ST   |
| 111       | lineage4 | LAM         | DR           | S31ST   |
| 115       | lineage4 | LAM         | DR           | S31ST  S302R |
| 130       | lineage4 | LAM         | MDR          | S450L  S31ST |
| 143       | lineage4 | LAM         | DR           | S31ST   | C16T |
| 144       | lineage4 | CAS         | MDR          | S450L  S31ST |
| 146       | lineage3 | CAS         | MDR          | S450L  S31ST | V128G |
| 151       | lineage3 | CAS         | MDR          | S450L  S31ST | V128G  Q497R |
| 100-S17   | lineage3 | CAS         | MDR          | S450L  S31ST | V128G  Q497R |
| 101-S16   | lineage4 | LAM         | MDR          | S450L  S31ST, S302R | D49G  Q497R |
| 113-S15   | lineage4 | LAM         | DR           | S31ST   |
| 114-S19   | lineage4 | LAM         | MDR          | S450L  S31ST | D63A |
| 132-S10   | lineage4 | LAM         | DR           | S31ST   |
| 134_      | lineage  | CAS         | MDR          | S450L  S31ST | G406S |
mutations into clinical practice and investigate their association with participant’s health outcomes. In this study, participants with MDR-TB were cured using the recommended treatment regimen and reverted late to culture negativity as compared to those with mono- or poly-resistance (Table 4). Time to culture conversion was

| Isolate ID | Lineages | Spoligotype | WGS cluster | Genotype at drug loci | RIF rpoB | ZN katG | AMK pncA | PZ gyrB | FLR | AMG embB | EMB embC | embA rpsL | rs rrs |
|------------|----------|-------------|-------------|-----------------------|----------|--------|---------|--------|-----|---------|--------|---------|--------|
| S8         | 3        |              |             |                       |          |        |         |        |     |         |        |         |        |
| 137-S22    | lineage2 | Beijing     | MDR         | S450L, S315T          |          |        |         |        |     |         |        |         |        |
| 139-S17    | lineage1 | EAI         | DR          |                       |          |        |         |        |     |         |        |         |        |
| 140-S21    | lineage1 | EAI         | DR          | OxyR-ahpC, CS2T,      | A193AT   |        |         |        |     |         |        |         |        |
| 141-S1     | lineage4 | LAM         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 145-S11    | lineage2 | Beijing     | MDR         | S450L, S315T, P69L    |          |        |         |        |     |         |        |         |        |
| 17-S14     | lineage4 | LAM         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 301-S24    | lineage3 | CAS         | MDR         | S450L, S315T, CS17T   | A193AT   |        |         |        |     |         |        |         |        |
| 342-S10    | lineage3 | CAS         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 43-S19     | lineage4 | LAM         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 44-S20     | lineage3 | CAS         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 50-S18     | lineage3 | CAS         | MDR         | S450L, S315T, V128G   |          |        |         |        |     |         |        |         |        |
| 56-S6      | lineage4 | LAM         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 60-S3      | lineage4 | LAM         | DR          | S450L                 |          |        |         |        |     |         |        |         |        |
| 73-S5      | lineage3 | CAS         | DR          | S450L                 |          |        |         |        |     |         |        |         |        |
| 78-S15     | lineage4 | LAM         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 79-S12     | lineage4 | LAM         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 80-S3      | lineage3 | CAS         | DR          | M306I                 |          |        |         |        |     |         |        |         |        |
| 89-S18     | lineage4 | LAM         | MDR         | S450L, S315T, V128G   |          |        |         |        |     |         |        |         |        |
| 90-S23     | lineage3 | CAS         | MDR         | S450L, S315T, V128G   |          |        |         |        |     |         |        |         |        |
| 91-S8      | lineage3 | CAS         | MDR         | S450L, S315T, V128G   |          |        |         |        |     |         |        |         |        |
| 94-S14     | lineage3 | CAS         | MDR         | S450L, S315T          |          |        |         |        |     |         |        |         |        |
| 96-S11     | lineage1 | EAI         | MDR         | S450L, S315T          |          |        |         |        |     |         |        |         |        |
| 99-S4      | lineage4 | LAM         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 523        | lineage4 | LAM         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |
| 59         | lineage3 | CAS         | DR          | S315T                 |          |        |         |        |     |         |        |         |        |

**RIF** Rifampicin, **INH** Isoniazid, **AMK** Amikacin, **PZ** Pyrazinamide, **FLR** Fluoroquinolones, **AMG** Aminoglycosides, **EMB** Ethambutol, **ST** Streptomycin

Table 5 Description of lineages, spoligotype, cluster of drug resistance *M. tuberculosis* and genotype at important drug loci (Continued)
findings by Meressa et al., [44] in Ethiopia. This success study participants achieved treatment success, similar to mines treatment outcomes. Fortunately, 82.5% (47/57) of that predict phenotypic resistance to anti-TB drugs deter-
spectively. In addition, the spectrum of mutations to genes culture negativity after 125 and 77 days of treatment re-
India and Ethiopia who documented reversion time to find-
tion free of TB [45]. Over 17% of study participants had unfavourable treatment outcomes (5% mortality and 12% lost-to- follow-up), similar to that reported by Meressa et al., [44] in Ethiopia. This success rate is 30% higher than the global MDR-TB treatment success rate [15], positioning the WGS method along with culture based DST as a useful testing algorithm for rigor-
ous microbiological monitoring that will accelerate the 2035 strategic END-TB vision to create a world population free of TB [45]. Over 17% of study participants had unfavourable treatment outcomes (5% mortality and 12% lost-to- follow-up), similar to that reported by Meressa et al., [44]. However, this is lower than that reported by Dheda et al., [46] and Milanov et al., [47] in South Africa and Bulgaria who both documented over 50% unfavourable treatment outcomes. Previous findings have argued that severe malnutrition (BMI < 16 kg/m2), HIV co-
fection, previous history of anti-TB therapy and drug ad-
verse events can predict poor treatment outcomes [47, 48]. In this study, 29.9% of the study participants had low BMI and 23% were infected with HIV but had no effects on MDR-TB treatment outcomes.

In our study, the phylogenetic analysis showed distinct DR-TB spoligotype lineages similar to a previous finding by Kideny et al. [49] in North-western Tanzania who reported strain variation across different spoligotype-defined *M. tuberculosis* lineages. We found that, the Central Asian strains (CAS) genotype (lineage 3) were the predominant lineages (Table 5), with no evidence of any change in terms of the CAS dominance over the past few years in Tanzania [50]. The CAS is among the prevalent lineage in the Indian subcontinent, South-East Asia, the Middle-East and East-Africa [51], showing a North-South divide along the Tropic of Cancer in the Eastern hemisphere – mainly in Asia, and partly prolonged along the horn of Africa [51, 52]. The dominance of CAS lineages in our local settings might be attributed to early contact due to migration and trade between people in Asian and East Africa countries. The seem-
ingly prolonged stable dominance of CAS lineage reflects limited movement in of new infections from other sources/origins to influence the constantly circulating strains.

The main strength of our study is that we have corre-
lated and linked WGS with treatment response and out-
comes in a resource limited clinical TB endemic setting like Tanzania, which was not available previously. WGS provides high resolution when investigating diseases transmission in outbreaks, provides results for 2nd line drugs which is currently not performed in our settings. In addition to that, the WGS enables earlier use of the most appropriate drug regimen, thus improving patient outcomes and reducing overall healthcare costs [33]. This is the first step to start thinking how this technol-
ogy could be included and add value in the future DR-
TB diagnosis cascade, in high burden areas with limited resources where the need for rapid and accurate tools for assisting clinical decision making for optimal patient care and in predicting the treatment outcomes is very high.

However, our study has some limitations. Phenotypic culture-based DST for PZA, and cycloserine, which were part of the standardized treatment regimen for all participants was missing. In addition, concordance between line probe assays (LPA) genotype MD8TDRplus and MTBDRs and WGS could not be done, which would have given a full comparison of the robustness of the WGS since the former had not been in use at the time of the study. In addition, WGS was performed retro-
spectively on clinical isolates, genetic data was not ap-
plied in the real time in the clinical setting, and hence no treatment regimen was modified to favour outcomes. Moreover, the use of WGS on frozen isolates of *M. tu-
berculosis* does not allow us to make considerations and comparisons between Xpert®MTB/Rif assay, phenotypic DST and WGS. Finally, WGS provides rapid and com-
prehensive diagnosis of DR-TB and the WHO has recog-
nized its great potential for rapidly diagnosing drug-
resistant TB in diverse clinical settings. However, there are challenges that need to be overcome prior to the im-
plementation of whole-genome sequencing in resource-
limited countries. These include high cost of equipment, the requirement for technical training, the need for ex-
pert guidance on the clinical interpretation of WGS data as the kind of information provided from the previous typing methods, the lack of simple solutions to obtain genome sequencing information directly from sputum samples and how it can be accommodated into our pre-
extisting diagnostic frameworks. Nevertheless, the useful information presented in this study outweighs these lim-
itations and can be used to advocate for a policy change in the adoption of molecular TB diagnostic algorithms.

**Conclusion**

WGS uncovered mutations in genes that predict pheno-
typic resistance to anti-TB drugs, signifying its import-
ance in informed decision making prior to anti-
tuberculosis therapy. Expectedly, WGS was robust in ruling out DR-TB especially in absence of detectable mutations, which was the case in drug susceptible *M. tu-
berculosis* clinical isolates. The WGS-based DST best
correlated with culture conversion rates and treatment outcome, indicating its potential application in designing an optimally individualized treatment regimen for favourable treatment outcomes in TB endemic settings.

Methods

Study settings
This study was conducted at Kibong’oto Infectious diseases hospital (KIDH) in Siha District, Kilimanjaro region, Tanzania. KIDH is the national centre of excellence for clinical management of drug resistant TB in the country and has a bed capacity of 320. The hospital provides TB services to more than 150 and 500 patients with drug resistant and susceptible TB per year, respectively. Recruitment and spuata collections from study participants were done at KIDH. Xpert® MTB/Rif assay, smear microscopy for acid-fast bacilli (AFB) and isolation of MTBC on Lowenstein-jensen (LJ) solid medium was performed at KIDH Mycobacteriology laboratory. MTBC isolates were transported to the Central Tuberculosis Reference Laboratory (CTRL) located at Muhimbili National Hospital (MNH) in Dar-es-salaam, Tanzania, for phenotypic susceptibility testing (DST) to first- and second-line anti-TB drugs like RIF, INH, EMB, SM, ofloxacin (OFX) and Kanamycin/Amikacin (KAN/AMK) and DNA extraction. Due to its complexity, PZA-DST is not routinely performed in Tanzania. MTBC DNA were shipped to London School of Hygiene and Tropical Medicine (LSHTM) for WGS and bioinformatics analysis.

Study design, population and recruitment of participants
This study involved 57 and 30 participants who harboured M. tuberculosis that were resistant and susceptible to anti-TB drugs respectively, presenting at KIDH during the study period in 2014. Participants with resistant isolates were recruited if they had laboratory results by either GeneXpert MTB/RIF or phenotypic culture and DST [16]. The drug resistance was either mono/polyresistance-resistant or MDR-TB. The rest were recruited if they were infected with MTB that was susceptible to RIF by Xpert® MTB/Rif assay. Eligibility included age ≥18 years, and willingness to sign a written informed consent and provide sputum samples for laboratory analysis. Very sick participants were excluded from the study.

Data collection
A standardized semi-structured questionnaire containing a set of study variables was used to collect data from study participants and medical charts were used to monitor treatment. Pre-treatment data that was collected included clinical information such as symptoms and signs suggestive of pulmonary tuberculosis (PTB), any previous history of TB treatment, HIV status, absolute CD4 + T cell count, the body mass index as the ratio of weight (kg) and (height)² (m²) and socio-demographic characteristics such as age and gender. MDR-TB was treated for at least 20 months and monitored monthly with culture and smear microscopy for AFB while DS TB was monitored with smear microscopy only to determine microbiological treatment response and programmatic outcomes. WGS was performed on baseline MTBC isolates.

Laboratory procedures

Samples collection, culture of MTBC and phenotypic drug-susceptibility testing
Each study participant provided approximately 4 mL of one spot sputum samples for culture. The samples were processed using the modified Petroff method [31]. Briefly, 4 mLs of sputum was added to 4 mLs of 4% sodium hydroxide (NaOH). The mixture was vortexed and left to stand at room temperature for 15 min. Thereafter, the volume of the mixture was adjusted to 50 mLs in a falcon tube and concentrated by centrifugation at 3000 g for 15 min. Supernatants were discarded into a container with 25% phenol. Sediments were suspended in Phosphate buffer saline solution (PBS) before being inoculated on LJ culture media as recommended by the Clinical and Laboratory Standard Institute (CLSI) for TB culture [22]. In summary, 200 μL of sputum sediments were inoculated on two slopes of LJ medium containing either pyruvate or glycerol. Culture and identification of MTBC colonies were performed according to locally existing and CLSI standard operating procedures. Phenotypic drug susceptibility testing of the MTBC isolates was performed using a standard proportion method on LJ media [53, 54].

DNA extraction and whole genome sequencing

Genomic DNA was extracted at Muhimbili University of Health and Allied Sciences (MUHAS) using a modified protocol based on Restriction Fragment Length Polymorphism (RFLP) developed at the National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands [55]. The concentration and quality of the DNA were measured using Qubit™ 4 Fluorometer (Invitrogen®). DNA samples were shipped to London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom for whole genome sequencing. The DNA were shipped in screw capped cryo-vials and sealed with parafilm materials. During shipment the DNA were packed in double box and transported in iced packed with insulators materials in a thermo-stable shipping box where the Styrofoam was at least 1.5 in. thick. Library preparation, cluster amplification and sequencing were performed according to the manufacturer’s instructions.
(QIAGEN). The QIAsym FX DNA Library Kit (QIAGEN) was used for library preparation according to the manufacturer’s protocol. The QIAsym FX DNA Library Kit covers DNA fragmentation for 15 min, adapter ligation and a final purification of the samples using AMPure XP beads (Beckman-Coulter). Library DNA content was analysed using a Qubit 3.0 fluorometer. The sizes of DNA fragments were quantified using the Agilent High Sensitivity DNA Kit (Agilent Technologies) on an Agilent 2100 Bioanalyser (Agilent Genomics) according to the manufacturer’s protocol. Samples were pooled to create pools of libraries at a concentration between 10 and 12pM, and loaded into the MiSeq using MiSeq® v2 Reagent Kit. WGS was performed at the LSHTM using MiSeqTM Sequencing 172 System MiSeqV2–500 cycles (Illumina), producing paired-end sequence reads of 151 bp.

Bioinformatics and genomic data analysis

Quality control and mapping of reads

Initial quality control (QC) reads were characterized using Kraken version v1.1 to exclude contamination and low-quality reads bases of less than 20 Qscore (defined as -10log10 (P), where P is the probability of an error as determined by the sequencing platform). Quality reads were mapped to the H37Rv reference genome (AL123456) using BWA mem [56] with default settings. The median depth and the percentage of the reference covered by a minimum of 10 reads were calculated using SAMtools depth [56] and custom scripts. Samples with sufficient amounts of MTBC data were used for downstream analysis.

Variant calling and in-silico resistance and lineage typing

Variants in drug resistance candidates were called using LoFreq version v2.1.2 [57]. These were annotated and compared to the TBProfiler database [58] (http://tbdr.lshtm.ac.uk/) as it does not perform its own variant calling but annotates existing calls as drug resistance mutations using a database of mutations. Additionally, large indels were identified by looking at depth in candidate genes. The coverage across lineage specific markers was inspected using htsbox (https://github.com/lh3/htsbox) and custom scripts to assign specific lineages to the isolates.

Phylogeny reconstruction

Variants throughout the whole genome were called using SAMtools/BCFTools version v1.9 [59]. The resulting variant call format (VCF) files were collated together filtering was performed. In short, sites in samples were marked as missing if less than 5 reads aligned to a position and monomorphic sites or those with greater than 10% missing data were removed. Using all SNPs, a maximum likelihood phylogeny was constructed using ExaML version v3.0.21, a state of the art tool for phylogenomic analyses [60]. The phylogenetic reconstruction was used in conjunction with lineage predictions output by TBProfiler. These predictions were based on the universally adopted lineage nomenclature and SNP barcode reported by Coll et al. [61]. This was visualized with drug resistance phenotypes and lineages using iTOL [62]. The lineages were assigned based on the SNP barcode available at doi:https://doi.org/10.1038/ncomms5812 and has been adopted as the standard for Mtb WGS data.

Analysis of clinical data

Descriptive statistics was performed for demographic characteristics, frequency and distribution of mutation patterns in MDR-TB and other resistance patterns in MTBC. A Pearson chi-square test was used to determine the association between age, gender, HIV status and CD4 counts if applicable, Body mass index (BMI), history of previous TB treatment and genotype drug resistance as the main outcome using STATA version 14 (StataCorp LP, College Station, TX, USA). A p-value of < 0.05 considered statistically significant. Genotype drug resistance was defined as any mutations that are known to confer decreased anti tuberculosis drug susceptibility. Skewed data, Student’s -test and Wilcoxon rank-sum tests were used for normally distributed data. The body weight based on BMI values for both adults was categorized into two groups namely; thinness (< 18.5) and normal> 18.5 as recommended by the World Health Organization (WHO). Kappa statistics (K) were used to determine agreement between drug susceptibility testing (DST) and genetic drug resistance using four levels of agreement for kappa: < 0.40 (poor), 0.40–0.59 (fair), 0.60–0.80 (good), and > 0.80 (excellent) [63].

Abbreviations

AIDS: Acquired immunodeficiency syndrome; BMI: Body mass index; DR-TB: Drug resistant tuberculosis; DS-TB: drug susceptible tuberculosis; HIV: Human immunodeficiency virus; KIDH: Kibong’oto infectious diseases hospital; LJ: Lowerensten jensend; MDR-TB: Multidrug resistant Tuberculosis; MTB: Mycobacterium tuberculosis; PTB: Pulmonary tuberculosis; SNP: Single nucleotide polymorphism; TB: Tuberculosis; WHO: World health organization; XDR-TB: Extensive DR-TB

Acknowledgments

We acknowledge laboratory staff of the Central Referral Tuberculosis Laboratory, Biochemistry Department at Muhimbili University of Health and Allied Science and the Director of Kibong’oto hospital for their logistic support during the execution of this study.

Authors’ contributions

BZK and PMM conceived the idea, designed the study; developed data collection tool; acquired, analyzed and interpreted data; drafted and revised the manuscript. NAL participated in data collection and performed initial laboratory work; SC performed the laboratory work; JDK, MM, EVM, SEM, MMR, SM and HMD contributed to conceptual, commented the manuscript and critically reviewed it; JEP analyzed and interpreted data, under the supervision of TGC and SC, and revised the manuscript; TGC and SC.
supervised the laboratory work and reviewed the manuscript; MIM conceived the idea, designed the review, interpreted data into metanarratives, reviewed the manuscript and supervised the entire process. All authors read and approved the final version of this review before submission.

Funding
The study was funded by the Wellcome Trust Grant [WT087546MA] and the United Republic of Tanzania through the Ministry of Health, Community Development, Gender, Elderly and Children for funding this study. PMM was supported by the Deltas Africa Initiative [Afrique One-ASPINE /DEI-15-008]. Afrique One-ASPINE is funded by a consortium of donors including the African Academy of Sciences (AAS), Alliance for Accelerating Excellence in Science in Africa (AESAf), the New Partnership for Africa’s Development Planning and Coordinating (NEPAD) Agency, the Wellcome Trust (107753/A/15/2), and the UK government. PMM was also supported by the EdCTP 2 programme Senior Fellowship for Dr. Stella Mpagama (TMA 2016–1463). TGC is supported by the Medical Research Council UK (Grant no.R00353/1, MR/ M01360X/1, MR/013063/1 and BSBC (BS/B01/3063/1). SC is funded by the Medical Research Council UK (Grant no. MR/M01360X/1 and BSBC (BS/B01/3063/1). The funders had no part in study design, data collection and interpretation, or the decision to submit the work for publication.

Availability of data and materials
Raw sequence data are available from the European Nucleotide Archive (ENA) under the project accession number PRJEB29435 (https://www.ebi.ac.uk/ena/data/view/PRJEB29435).

Ethics approval and consent to participate
The Senate Research and Publications Committee of the Muhimbili University of Health and Allied Sciences (Muhimbili) in Tanzania approved the study (Ref. No. MU/PGS/PhD/Vol/IV/154). Permission to conduct the study was obtained from KIDH administration. Prior to any study procedure, we obtained written informed consent that was signed by all patients. All study participants received MDR-TB treatment according to existing National and global MDR-TB treatment guidelines in Tanzania [23, 27].

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interest related to this article.

Author details
1Department of Microbiology and Immunology, School of Medicine, Muhimbili University of Health and Allied Sciences (Muhimbili), Dar es Salaam, Tanzania. 2Tanzania Wildlife Research Institute (TAWIRI), Arusha, Tanzania. 3Kibong’o Infectious Disease Hospital (KIDH), Manyara, Tanzania. 4Department of Global Health and Biomedical Sciences, School of Life Sciences and Bioengineering, Nelson Mandela African Institution of Science and Technology (NM-AIST), Arusha, Tanzania. 5Field Epidemiology and Laboratory Training Programme, Dar es Salaam, Tanzania. 6Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine (LSHTM), Keppel Street, London WC1E 7HT, UK. 7Department of Medical Microbiology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania. 8Southern African Centre for Infectious Diseases Surveillance (SACIDS), Sokoine University of Agriculture (SUA), Morogoro, Tanzania. 9Department of Biochemistry, Muhimbili University of Health and Allied Sciences (Muhimbili), Dar es Salaam, Tanzania. 10Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine (LSHTM), Keppel Street, London WC1E 7HT, UK.

Received: 4 July 2019 Accepted: 12 February 2020

Published online: 21 February 2020

References
1. Raviglione M, Sulis G. Tuberculosis 2015: burden, challenges and strategy for control and elimination. Infectious disease reports. 2016;8:6570.
2. WHO. Global Tuberculosis Report 2017. World Health Organization 2017.
3. Narasimhan, P., Wood, J., MacIntyre, C. R & Mathai, D. 2013. Risk Factors for Tuberculosis. Pulm Med V 2013, Article ID 828939, 11 pages. http://dx.doi.org/10.1155/2013/828939
4. Kharasny ABM, Karim QA. HIV infection and AIDS in sub-Saharan Africa: current status, challenges and opportunities. Open AIDS J. 2016;10:34–48.
5. W.H.O. World Tuberculosis Day 2019. https://www.afro.who.int/media-centre/events/world-tuberculosis-day-2019
6. Albert H, Nathavitharana RR, Isaacs C, Boehme CC, C. C. Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better? Eur Respir J. 2016;48:2516−25.
7. Musa, B.M., Adamu A.L., Galadanci, N.A., Zubayr, B., Odoh, C.N., Aliyu, M.H. 2017. Trends in prevalence of multi drug resistant tuberculosis in sub-Saharan Africa: A systematic review and meta-analysis. PLoS One 12(9), e0181505. https://doi.org/10.1371/journal.pone.0181505
8. Dye, C., Harries, A.D., Baloyi, M., Nkhoma, W & Salaniponi, F.M. 2006. Disease and mortality in sub-Saharan Africa. 2nd edition. In Jamison DT, Feachem RG, Makgoba MW, Bos, E.R., Baingana, F.K., Hofman, K. J & Rogo, K.O. Washington (DC): the International Bank for Reconstruction and Development / the World Bank; 2006. ISBN-10: 0-8213-6397-2, ISBN-13: 978-0-8213-6397-3.
9. Espinal MA, Laszlo A, Simonson L, Bouahibal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Birkin N, Dye C, Williams R, Raviglione MC. Global trends in resistance to anti-TB drugs. N Engl J Med. 2001;344:1294−303.
10. Chonde TM, Basra D, Mfninga SG, Range N, Livilla F, Shirima RP, van Deun A, Zignol M, Cebeloglu FG, Egwaga SM, van Leth F. National anti-tuberculosis drug resistance study in Tanzania. TUBITAL. 2010;14(8):967−9726.
11. Glynn JR. Resurgence of tuberculosis and the impact of HIV infection. Br Med Bull. 1998;54:79−93.
12. W.H.O. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. Geneva: World Health Organization; 2014.
13. Foongladla S, Banu S, Pholwat S, Gratz J, O-Thong S, Nakkerd N, Chirili R, Ferdous SS, Rahman SMA, Rahman A, Ahmed S, Heyesell S, Sankh M, Kibiki G, Houpf E. Comparison of TaqMan® Assay card and MYCOTB with conventional phenotypic susceptibility testing in MDR-TB. Int J Tuberc Lung Dis. 2016;20:1105−12.
14. Chonde TM, Basra D, Mfninga SG, et al. National anti-tuberculosis drug resistance study in Tanzania. Int J Tuberc Lung Dis. 2010(14):967−972.
15. W.H.O. WHO treatment guidelines for drug-resistant tuberculosis 2016. Geneva, 2016.
16. Mbelebe PM, Aboub S, Mpagama SG, Matee MI. Improved performance of Xpert MTB/RIF assay on sputum sediment samples obtained from presumptive pulmonary tuberculosis cases at Kibong’o infectious diseases hospital in Tanzania. BMC Infect Dis. 2017;17:808.
17. Karimi H, En-Nanali L, Oudghiri A, Chauai L, Laglaoui A, Boukari JD, El-Msibri M, Abid M. Performance of GenoType® MTBDRplus assay in the diagnosis of drug-resistant tuberculosis in Tangier, Morocco. J Glob Antimicrob Resist. 2017;12:63−7.
18. Theron G, Peter J, Richardson M, Warren R, Dhedka K, Steingart KR. GenoType® MTBDRs1 assay for resistance to second-line anti-tuberculosis drugs. The Cochrane database of systematic reviews. 2016;3(2)100705.
19. Sotiou G, Tiberi S, Gentis R, D’Ambrosio L, Fuentes Z, Zumla A, Migliori GB. Applicability of the shorter &lt;2018Bangladesh regimen&gta;2019, in high multidrug-resistant tuberculosis settings. Int J Infect Dis. 2017;56:190−3.
20. Feliciano CS, Namburete EI, Apaça JR, K Peronni, Dippinara A, Warren RM, Silva WAJ, Bollela VR. Accuracy of whole genome sequencing versus phenotypic (MGIT) and commercial molecular tests for detection of drug-resistant mycobacterium tuberculosis isolated from patients in Brazil and Mozambique. Tuberculosis. 2018;110:59−67.
21. Chattejee A, Nilgiriswala K, Karanath D, Rodrigues C, Mistry N. Whole genome sequencing of clinical strains of mycobacterium tuberculosis from Mumbai, India: A potential tool for determining drug-resistance and strain lineage. Tuberculosis. 2017;107:63−72.
22. Quan TP, Bawa Z, Foster D, Walker T, Elias CDO, Rashid P, M, M. M. I, Group, Izbil Z, Bradley P, Movbray J, Walker AS, Crook DW, Wyllie DH, Peto T, Smith SG. Evaluation of whole-genome sequencing for mycobacterial species identification and drug susceptibility testing in a clinical setting: a large-scale prospective assessment of performance against line probe assays and Phenotypix. J Clin Microbiol. 2018;56:e01480−17.
23. Shea J, Halse TA, Lapiere P, Shutt M, Kohlerschmidt D, Van Roey P, Limberger R, Taylor J, Escuyer V, Musser KA. Comprehensive whole-genome
sequencing and reporting of drug resistance profiles on clinical cases of mycobacterium tuberculosis in New York state. J Clin Microbiol. 2017;55:1871–82.

24. Walker, T. M., T. A. Kohl, S. V. Omar, J. Hedge, C. Del Ojo Elias, P. Bradley, Z., Iqbal, S., Feuerriegel, K. E., Niehaus, D. J., Wilson, D. A., Clifton, G., Kapata, C. L. C., Io, R. Bowden, F. A., Drobniewski, F., Allix-Béguec, C., Gaudin, J., Parkhill, R., Dieu, P., Supply, D. W., Crook, E. G., Smith, N., Ismail, S., Niemann, T. A. E. Peto, and G., Medeming Medical Microbiology Informatics. 2015. Whole-genome sequencing for prediction of mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect Dis 15:1193–1202.

25. Pang, Y., Dong, H. Tan, Y., Deng, Y., Cai, X., Jing, H., Xia, H., Li, Q., Ou, X., Su, B., Li, X., Zhang, Z., Li, J., Zhang, J., Huan, S., Zhao, Y. Rapid diagnosis of MDR and XDR tuberculosis with the MetPro TB assay in China. Sci Rep. 2016;6:25330.

26. Shah, M. A., Shah, I. Increasing prevalence of pediatric drug-resistant tuberculosis in Mumbai, India, and its outcome. Pediatr Infect Dis J. 2018;37:1261–3.

27. Chen, J., Peng, P., Du, Y., Ren, Y., Chen, L., Rao, Y., Wang, W. Early detection of multidrug- and pre-extensively drug-resistant tuberculosis from smear-positive sputum by direct sequencing. BMC Infect Dis. 2017;17:300.

28. Motto, P., Tessera, B., Taglioni, E., Chindelevitch, L., Starks, A. M., Emerson, C., Hanna, D., Kim, P.S., Livski, R., Zignol, M., Gilpin, C., Niemans, D., Denker, CM., Fleming, J., Warren, RM., Crook, D., Posey, J., Gagneux, S., Hoffner, S., Rodrigues, C., Comas, I.A., Engeltreich, DM., Murray, M., Alland, D., Rigouts, L., Lange, C., Dheda, K., Hsiao, R., Ranganath, U., McKee, M., Ezezuo, M., Cirillo, DM., Schito, M., Kxaser, G., Reddell, T. A., Fennelly, E. P. A standardized method for interpreting the association between mutations and phenotypic drug resistance in mycobacterium tuberculosis. Eur Respir J. 2017;50:1701354.

29. Mbelele, P., Mohamed, S., Sauli, E., Mpolya, E., Mfinanga, S., Addo, K., Heyssel, S., Mpanga, S. Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults. International Journal of Microbiology. 2018;7:299–309.

30. Papaventsis, D., Casali, N., Kontsevaya, I., Drobniewski, F., Cirillo, DM., Mbelele, P., Mohamed, S., Sauli, E., Mfinanga, S., Addo, K., Heyssel, S., Mpanga, S. Meta-narrative review of molecular methods for diagnosis and monitoring of multidrug-resistant tuberculosis treatment in adults. International Journal of Microbiology. 2018;7:299–309.

31. Witney, A. A., Gough, K. A., Arnold, A., Coleman, D., Delgado, R., Dhillon, J., Pond, M., Pope, C.F., Planche, TD., Stoker, NG., Cosgrove, CA., Butcher, PD., Harrison, TS., Hinds, J. Clinical application of whole-genome sequencing to inform treatment for multidrug-resistant tuberculosis cases. J Clin Microbiol. 2015;53:1473–83.

32. McNevery, R., Clark, TG., Campino, S., Rodgers, C., Dolinger, D., Smith, L., Iqbal, S., Rahmam, A., Ameni, G., Bjune, G., Couvin, D., Rastogi, N., Abebe, F., Allix-Béguec, C., Gaudin, J., Pain, A., Rigouts, L., Clark, TG., Warren, RM., Alland, D., Dheda, K., Limberis, JD., Pietersen, E., Phelan, J., Esmail, A., Lesioskoi, M., Posse, J., Lele, R., Mastrapa, B., Streicher, EM., Dolby, T., Abdallah, AM., Ben-Rached, F., Simpson, J., Smith, L., Gumbo, T., van Helden, P., Sigel, FA., McNevery, R., Theorion, P., Pain, A., Clark, TG., Warren, RM., Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study. Lancet Respir Med. 2017;5:269–81.

33. Milanov, V., Falzon, D., Zamfirova, M., Varleva, T., Bachysska, E., Koleva, A., Dara, M. Factors associated with treatment success and death in cases with multidrug-resistant tuberculosis in Bulgaria, 2009–2010. Int J Mycobacteriol. 2015;4:131–2.

34. Umanah, T., Ncayiyana, J., Padanilam, Y. Treatment outcomes in multidrug resistant tuberculosis-human immunodeficiency virus co-infected patients on anti-retroviral therapy at Sizwe tropical disease hospital Johannesburg, South Africa. BMC Infect Dis. 2015;15:478.

35. Kidunya, B.R., Mihana, S.E., Fitzgerald, D.W., Ochtera, D.I. Genotypic drug resistance using whole-genome sequencing of mycobacterium tuberculosis clinical isolates from North-Western Tanzania. Tuberculosis. 2018;109:97–101.

36. World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update WHO/HTM/TB/2016.04. Geneva: World Health Organization; 2016. Available from: http://www.who.int/tb/MRDTBguidelines2016.pdf.

37. Belay, M., Aremu, B.J., Gbujie, C., Couvin, D., Rastogi, N., Abebe, F. Strain diversity of mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Addis ababa pastoral region of Ethiopia. Biomed Res Int. 2014;2014:238532.

38. Mbogi, E.V., Katala, B.Z., Streicher, EM., Kkeyu, J.D., Kendall, SL., Dockrell, HM., Michel, AL., Rwiyenerwemu, MM., Warren, RM, Matee, MI., van Helden, PD., Couvin, D., Rastogi, N. Mapping of mycobacterium tuberculosis complex genetic diversity profiles in Tanzania and other African countries. PLoS One. 2016;11:e0154571.

39. Matee, M., Mei, L., Louansaava, T., Wieland-Alter, W., Waddell, R., Lyimo, J., Bakari, B., Collange, K., van Reyn, CF., Sputum microscopy for the diagnosis of HIV-associated pulmonary tuberculosis in Tanzania. BMC Public Health. 2008;8:688.

40. Yurtsever, G., Biçmen, C., Gündüz AT., Ozkutuk, N., Salaman, S., Demirci, M. Comparison of proportion method in Löwenstein-Jensen medium with the BACTEC 460 TB system for antimycobacterial susceptibility testing of Mycobacterium tuberculosis clinical isolates. Microbiol. 2011;45:623–31.

41. 2004142920.

42. ChYTIC Consortium and the 100,000 Genomes Project, Allix-Béguec, C., Arandjelovic, I., et al. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing. N Engl J Med. 2018;379(15):1403–15. https://doi.org/10.1056/NEJMoa1804747.

43. Patel, SJ., Nimavat KB, Patel, AB, Mehta KG, Shringarpure K, Shukla UK. Sputum smear and culture conversions in multidrug resistance tuberculosis patients in seven districts of Central Gujarat, India: A longitudinal study. Indian J Commun Med: Official Publication Indian Assoc Prev Soc Med. 2018;43:117–9.

44. Shibabaw, G., Gelaw, R., Wang, S-H., Teserra, B. Time to sputum smear and culture conversions in multidrug-resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia. PLoS One. 2018;13:e0198080.

45. Meressa, D., Hurdto, RM., Andrews, JR., Diao, E., Abato, K., Daniel, T., Prasad, P., Prasad, R., Fekade, B., Tedla, Y., Yusuf, H., Tadesse, M., Tefera, D., Ashenaft, A., Desta, G., Adayeray, G., Olson, K., Thim, S., Oldfield, AE. Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia: An observational cohort study. Thorax. 2015;70:1181–8.

46. W.H.O. The END TB Strategy: 2015–2035. [Internet]. Geneva: World Health Organization; 2015. Available from: http://www.who.int/tb/End_TB_brochure.pdf.
58. Coll F, McNerney R, Preston MD, Guerra-Assunção JA, Warry A, Hill-Cawthorne G, Mallard K, Nair M, Miranda A, Alves A, Perdigão J, Viveiros M, Portugal I, Hasan Z, Hasan R, Glynn JR, Martin N, Pain A, Clark TG. Rapid determination of anti-tuberculosis drug resistance from whole-genome sequences. Genome Medicine. 2015;7:51.

59. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetic parameter estimation from sequencing data. Bioinformatics (Oxford, England). 2011;27:2987–93.

60. Kozlov, A. M., A. J. Aberer, and A. Stamatakis. 2015. ExaML version 3: a tool for phylogenomic analyses on supercomputers. Bioinformatics (Oxford, England) 31:2577-2579.

61. Coll F, McNerney R, Guerra-Assunção JA, Glynn JR, Perdigão J, Viveiros M, Portugal I, Pain A, Martin N, Clark TG. A robust SNP barcode for typing Mycobacterium tuberculosis complex strains. Nat Commun. 2014;5:4812.

62. Letunic I, Bork P. Interactive tree of life (iTOL) v3: an online tool for the display and annotation of phylogenetic and other trees. Nucleic Acids Res. 2016;44:W242–5.

63. Ondimu, T. O., M. O. Grace, A. O. Samson, and S. A. Asito. 2017. Comparative study of smear microscopy, GeneXpert and culture and sensitivity assays in detection of mycobacterium tuberculosis on sputum samples among tuberculosis suspected cases in Nyamira County referral hospital. Mycobacterial diseases 7.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.